Shots:
- Earendil Labs has entered into a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibody programs in oncology
- Earendil Labs will lead antibody discovery & research through early clinical development for programs targeting certain pre-agreed target combinations, while Genentech will take over global clinical development & commercialization
- As per the deal, Earendil Labs will receive a $55M upfront payment, plus development, regulatory & sales milestone payments, representing a total deal value over $1.5B. Earendil Labs will also receive tiered royalties on net product sales
Ref: PRnewswire | Image: Earendil Labs & Genentech | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
